Best of BS Opinion: The mis-selling menace, Covid-19 vaccination, and more

Here's a selection of Business Standard opinion pieces for the day
 

The government announced on Tuesday that it had accepted a recommendation by the National Expert Group that vaccines approved by health regulators in the European Union, the United States, Japan, and the United Kingdom should be granted emergency use approval in India. In this context, our lead editorial notes that having eased requirements, the government’s next step must be to ensure that India’s spare vaccine capacity — it could be producing enough two-shot vaccines a year to inoculate half the world — is pressed into service.
 

After watching the government mess up its handling of Covid, people want a strategy, not participatory stunts, writes Vir Sanghvi
 

It may be hoped that the Sebi action in the Yes Bank case, including the punishment of responsible individuals, will help set a new trend of greater transparency, and better disclosure of risks, notes our second editorial.

Quote

“This decision will facilitate quicker access to such foreign vaccines by India would encourage imports including import of bulk drug material, optimal utilisation of domestic fill and finish capacity etc., which will in turn provide a fillip to vaccine manufacturing capacity and total vaccine availability…."

Ministry of Health and Family Welfare